ClinicalTrials.gg
CompletedNCT00936897Updated Feb 11, 2013Results posted

A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates

A Phase 3 interventional study of Ibandronate and Denosumab in Postmenopausal Osteoporosis, sponsored by Amgen. Completed. Open to female participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2013-02-11.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
833
Allocation
Randomized
Ages
55 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 31 studies testing denosumab in Osteoporosis, Postmenopausal — 1 open to participants now, 3 under way, 2 of them phase 3. Denosumab · Osteoporosis, Postmenopausal.

Enrollment
4th of 31
833 · median 278
Started
2009
with 3 others
Phase 3
17 of 31
1 open now
Registered
9th of 31
by date
Lead sponsor
12 of 31
Amgen

Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, this one is the 4th largest by enrollment, is one of 4 that started in 2009, is one of 17 in phase 3, and was the 9th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

1 of the 31 studies testing denosumab in Osteoporosis, Postmenopausal is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 55 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing denosumab in Osteoporosis, Postmenopausal, or all of them as a file.
02

Study summary

This is a multi-center, randomized, open-label, parallel group, study being conducted in the United States and in Europe in postmenopausal women. Approximately 800 subjects will be randomized across about 65 sites in a 1:1 ratio to either denosumab 60mg SC Q6M, or ibandronate 150mg PO QM.

03

Conditions studied

  • Postmenopausal Osteoporosis
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ambulatory, women (based on medical history) 55 years or older at screening
  • Postmenopause will be defined as no vaginal bleeding or spotting for at least 12 months
  • If the subject is 55 - 59 years old and there is uncertainty regarding menopausal status, confirmation of serum FSH (>= 50 mIU/mL) and serum estradiol (\<= 20 pg/mL) must be obtained
  • If the subject is 60 years or older, evaluation of FSH and estradiol levels is not needed to confirm menopausal status
  • Have received their first prescription of daily or weekly bisphosphonate therapy at least 1 month prior to screening
  • May have received
  • raloxifene, calcitonin, prior to initiation of daily orweekly bisphosphonate therapy.
  • up to 3 doses of monthly bisphosphonate prior to initiation of daily or weekly bisphosphonate therapy
  • calcium, and vitamin D
  • Hormone replacement therapy (e.g. estrogen use for mitigation of menopausal symptoms)
  • Subject has:
  • Stopped daily or weekly bisphosphonate therapy (is denoted as non-persistent) at least one month before the screening visit, or
  • Demonstrated low adherence to therapy assessed by a score of less than 6 on the OS-MMAS
  • Screening BMD (g/cm2) values, at the lumbar spine OR total hip, that occur within the following ranges, based on the particular scanner that is used:

GE Lunar Lumbar spine 0.700 \< or = BMD \< and = 0.940 Total hip 0.504 \< or = BMD \< or = 0.756

Hologic Lumbar spine 0.607 \< or = BMD \< or = 0.827 Total hip 0.454 \< or = BMD \< or = 0.698 Both the initial and the repeat DXA scan of the lumbar spine OR the total hip must meet the above eligibility criteria.

  • At least 2 lumbar vertebrae must be evaluable by DXA.
  • At least one hip must be evaluable by DXA (eg, no history of either bilateral hip replacement or pins in both hips)
  • Provide signed before any study-specific procedures are conducted

Exclusion criteria

Exclusion Criteria:

  • Any disorder that compromises the ability of the subject to give written and/or to comply with study procedures
  • Current or prior use of medications prescribed for osteoporosis treatment other than oral daily or weekly bisphosphonate
  • to receive oral ibandronate 150mg PO QM, including
  • to ibandronate 150mg PO QM or other constituents of ibandronate 150mg PO QM tablets
  • Abnormalities of the esophagus, which delay esophageal emptying such as stricture or achalasia
  • Inability to stand or sit upright for at least 60 minutes
  • Administration of any of the following treatments within 3 months of screening
  • Tibolone
  • Anabolic steroids or testosterone
  • Glucocorticosteroids (>= 5 mg prednisone equivalent per day for more than 10 days or a total cumulative dose of >= 50 mg)
  • Vitamin D deficiency [25(OH) vitamin D level \< 20 ng/mL (\<49.9 nmol/L)] - Repletion will be allowed and subjects may be re-screened
  • Evidence of any of the following per subject report, chart review or central laboratory result:
  • Significantly impaired renal function as determined by estimated less that 30mL/min/1.73 m2 determined by the central laboratory
  • Current hypo- or hypercalcemia based on the central laboratory reference ranges
  • Active gastric or duodenal ulcer; or any history of significant gastrointestinal bleed requiring hospitalization or transfusion
  • Known to have tested positive for , virus, or surface antigen
  • (except fully resected cutaneous basal cell or squamous cell carcinoma, cervical or breast ductal carcinoma in situ) within the last 5 years
  • Any metabolic bone disease or secondary cause of bone loss that is not controlled and may interfere with the interpretation of the findings
  • Previous participation in clinical trials with denosumab 60mg SC Q6M (regardless of treatment)
  • Received any solid organ or bone marrow transplant
  • Any laboratory abnormality which, in the opinion of the investigator, will prevent the subject from completing the study or interfere with the interpretation of the study results
  • Known sensitivity to mammalian cell derived drug products
  • Known intolerance to calcium supplements
  • Currently enrolled in or has not yet completed at least 1 month since ending other device or drug trial(s)
  • Any physical or psychiatric disorder which, in the opinion of the investigator, will prevent the subject from completing the study or interfere with the interpretation of the study results
  • Evidence of alcohol or substance-abuse within the last 12 months which the investigator believes would interfere with understanding or completing the study
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
833 participants (actual)

Study arms

  • Active comparator
    Ibandronate

    Ibandronate 150mg PO QM (tablet)

    Drug: Ibandronate

  • Experimental
    Denosumab

    denosumab 60mg Subcutaneous Q6M (pre-filled syringe)

    Drug: Denosumab

Interventions

  • Ibandronate 150mg PO QM (tablet)

  • denosumab 60mg SC Q6M (pre-filled syringe)

06

What researchers measure

Primary outcomes

  1. Total Hip Bone Mineral Density Percent Change From Baseline at Month 12

    Time frame: Baseline to month 12

Secondary outcomes

  1. Serum Type-1 C-Telopeptide Percent Change From Baseline at Month 1

    Time frame: Baseline to month 1

  2. Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12

    Time frame: Baseline to Month 12

  3. Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12

    Time frame: Baseline to month 12

07

Results

Posted Nov 29, 2012

Participant flow

Participants were randomized from 29 July 2009 through 5 November 2010

Participant flow — Overall Study
MilestoneDenosumab 60 mg SC Q6MIbandronate 150 mg PO QM
Started417416
Completed398356
Not completed1960
Withdrew: Withdrawal by subject919
Withdrew: Adverse event413
Withdrew: Other39
Withdrew: Lost to follow-up110
Withdrew: Administrative decision12
Withdrew: Protocol violation11
Withdrew: Ineligibility determined03
Withdrew: Noncompliance02
Withdrew: Death01

Outcome measures

PrimaryTotal Hip Bone Mineral Density Percent Change From Baseline at Month 12
Time frame:
Baseline to month 12
Reported as:
Mean · Percentage Change From Baseline
Total Hip Bone Mineral Density Percent Change From Baseline at Month 12
Percentage Change From BaselineDenosumab 60 mg SC Q6MIbandronate 150 mg PO QM
Total Hip Bone Mineral Density Percent Change From Baseline at Month 122.2 (2.0 to 2.5)0.9 (0.6 to 1.1)
Statistical analysis
  • Denosumab 60 mg SC Q6M vs Ibandronate 150 mg PO QM · ANCOVA · p = <0.0001 · Mean difference (net): 1.4 · 95% CI 1.0 to 1.8Denosumab - Ibandronate
SecondarySerum Type-1 C-Telopeptide Percent Change From Baseline at Month 1
Time frame:
Baseline to month 1
Reported as:
Median · Percentage Change From Baseline
Serum Type-1 C-Telopeptide Percent Change From Baseline at Month 1
Percentage Change From BaselineDenosumab 60 mg SC Q6MIbandronate 150 mg PO QM
Serum Type-1 C-Telopeptide Percent Change From Baseline at Month 1-81.1 (-88.0 to -70.9)-35.0 (-51.9 to -15.3)
Statistical analysis
  • Denosumab 60 mg SC Q6M vs Ibandronate 150 mg PO QM · Wilcoxon (Mann-Whitney) · p = <0.0001
SecondaryFemoral Neck Bone Mineral Density Percent Change From Baseline at Month 12
Time frame:
Baseline to Month 12
Reported as:
Mean · Percentage Change From Baseline
Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12
Percentage Change From BaselineDenosumab 60 mg SC Q6MIbandronate 150 mg PO QM
Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 121.7 (1.3 to 2.1)0.5 (0.1 to 0.9)
Statistical analysis
  • Denosumab 60 mg SC Q6M vs Ibandronate 150 mg PO QM · ANCOVA · p = <0.0001 · Mean difference (net): 1.2 · 95% CI 0.7 to 1.7Denosumab - Ibandronate
SecondaryLumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12
Time frame:
Baseline to month 12
Reported as:
Mean · Percentage Change From Baseline
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12
Percentage Change From BaselineDenosumab 60 mg SC Q6MIbandronate 150 mg PO QM
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 124.1 (3.7 to 4.5)2.1 (1.7 to 2.5)
Statistical analysis
  • Denosumab 60 mg SC Q6M vs Ibandronate 150 mg PO QM · ANCOVA · p = <0.0001 · Mean difference (net): 2.0 · 95% CI 1.5 to 2.5Denosumab - Ibandronate

Adverse events

Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ibandronate 150 mg PO QM—22/410 (5.4%)31/410 (7.6%)
Denosumab 60 mg SC Q6M—39/411 (9.5%)42/411 (10.2%)
Most frequent serious events
Showing 10 of 74
Most frequent serious events
EventIbandronate 150 mg PO QMDenosumab 60 mg SC Q6M
Cardiac failure congestiveCardiac disorders0/4103/411
Chest painGeneral disorders0/4103/411
Atrial fibrillationCardiac disorders0/4102/411
BradycardiaCardiac disorders0/4102/411
Sick sinus syndromeCardiac disorders0/4102/411
DiverticulitisInfections and infestations0/4102/411
Cerebrovascular accidentNervous system disorders0/4102/411
Atrioventricular block completeCardiac disorders1/4100/411
Cardiac tamponadeCardiac disorders1/4100/411
Coronary artery diseaseCardiac disorders1/4100/411
Most frequent other events
Most frequent other events
EventIbandronate 150 mg PO QMDenosumab 60 mg SC Q6M
ArthralgiaMusculoskeletal and connective tissue disorders23/41025/411
Upper respiratory tract infectionInfections and infestations9/41021/411

Baseline characteristics

Age Continuous
Age Continuous(Years)Denosumab 60 mg SC Q6MIbandronate 150 mg PO QMTotal
Mean67.2 ± 8.166.2 ± 7.866.7 ± 8
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Denosumab 60 mg SC Q6MIbandronate 150 mg PO QMTotal
Female417416833
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Denosumab 60 mg SC Q6MIbandronate 150 mg PO QMTotal
White or Caucasian348361709
Black or African American347
Hispanic or Latino544296
Asian347
American Indian or Alaska Native202
Other123
Native Hawaiian or Other Pacific Islander639
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Miller PD, Pannacciulli N, Malouf-Sierra J, Singer A, Czerwinski E, Bone HG, Wang C, Huang S, Chines A, Lems W, Brown JP. Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates. Osteoporos Int. 2020 Jan;31(1):181-191. doi: 10.1007/s00198-019-05233-x. Epub 2019 Nov 28. PubMed 31776637 ↗
  • Recknor C, Czerwinski E, Bone HG, Bonnick SL, Binkley N, Palacios S, Moffett A, Siddhanti S, Ferreira I, Ghelani P, Wagman RB, Hall JW, Bolognese MA, Benhamou CL. Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol. 2013 Jun;121(6):1291-1299. doi: 10.1097/AOG.0b013e318291718c. PubMed 23812464 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Nov 2011 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2012, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2009
First posted
Jul 10, 2009
Start
Jul 2009
Primary completionActual
Nov 2011
CompletionActual
Jan 2012
Results first posted
Nov 29, 2012
Last update
Feb 11, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00936897
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jul 10, 2009
Start date
Jul 2009
Primary completion
Nov 2011
Completion
Jan 2012
Results posted
Nov 29, 2012
Last update
Feb 11, 2013

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion